The abstract is read at the publisher; the summary is JClub's.
Nb64, a high-affinity intracellular nanobody engineered to bind active opioid receptors, rapidly suppresses transducer engagement, internalization, and downstream signaling, including native μOR-linked GIRK currents.
- Why it matters: Existing pharmacological and genetic tools cannot resolve opioid receptor signaling across cell types and subcellular compartments, limiting understanding of how OR states shape pain relief, reward, and dependence.
- What they did: Using structure-guided evolution, the authors optimized intracellular nanobodies to create an active-state-selective inhibitor (Nb64), then tested its effects on μOR signaling and organelle-targeted control, plus peptide-mediated cytosolic delivery.
- The result: In ventral tegmental area neurons and in mice, Nb64 reduced fentanyl-evoked dopamine release and behavioral responses, enabling precision, compartment-specific inhibition of native G protein-coupled receptor signaling in vivo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.